Tumour pain therapy;Tumorschmerztherapie

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 38, Issue 6, 2003, Pages 403-434

  Ohnesorge, H ^a   Siebrecht, D ^b   Gleim, M ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CANNABINOID; CELECOXIB; CODEINE; CORTICOSTEROID; DICLOFENAC; FENTANYL; FENTANYL CITRATE; FLUPIRTINE; HYDROMORPHONE; IBUPROFEN; INDOMETACIN; MORPHINE; NALOXONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; OXYCODONE; PALADON; PARACETAMOL; PHENAZONE; PIROXICAM; PROPYPHENAZONE; ROFECOXIB; THIAMAZOLE; TILIDINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

CANCER LOCALIZATION; CANCER PAIN; CONSTIPATION; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; DYSPHORIA; EUPHORIA; GASTROINTESTINAL SYMPTOM; HUMAN; MIOSIS; PRACTICE GUIDELINE; PREVALENCE; REVIEW; SIDE EFFECT; TREATMENT INDICATION;

ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; DENERVATION; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; NERVE BLOCK; PAIN;

EID: 0037861014     PISSN: 09392661     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39360     Document Type: Review

References (75)

1. Deutsche Krebsgesellschaft. Kurzgefasste Interdisziplinäre Leitlinien 2002. 2002; 3
2. Ensink FBM, Beck D, Bautz MT, Hanekop GG. Tumorschmerztherapie Teil 1: Prävalenz und Klassifikation von Tumorschmerzen. Niedersächsisches Ärzteblatt 1999; 72: 1-4
3. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330 (9): 592-596
4. Bonica JJ. Cancer pain, in: Bonica J.J. The management of pain. Lea & Fiebiger: Philadelphia/London, 1990: 400-460
5. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 1999; 82 (3): 263-74
6. Heidemann E. Malignome und Prävalenz von Schmerz, in: H. Beck, et al. Schmerztherapie Thieme: Stuttgart/New York, 2002: 515-517
7. Portenoy RK. Cancer pain. Epidemiology and syndromes. Cancer 1989; 63 (11 Suppl): 2298-2307
8. Twycross R. Cancer pain classification. Acta Anaesthesiol Scand 1997; 41 (1 Pt 2): 141-145
9. Deutsche Gesellschaft für Anästhesie und Intensivmedizin. Grenzen der intensivmedizinischen Behandlungspflicht. Anästhesie & Intensivmedizin 1999; 40 (2): 99ff
10. Gonzales GR, Elliott KJ, Portenoy RK, Foley KM. The impact of a comprehensive evaluation in the management of cancer pain. Pain 1991; 47 (2): 141-144
11. Schug SA, Zech D, Dorr U. Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage 1990; 5 (1): 27-32
12. World-Health-Organisation. Cancer pain relief. Genf: World Health Organisation, 1986
13. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 1995; 63 (1): 65-76
14. Ventafridda V, Tamburini M, Caraceni A, de Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer 1987; 59 (4): 850-856
15. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. Jama 1995; 274 (23): 1870-1873
16. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. Jama 2001; 286 (8): 954-959
17. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343 (21): 1520-1528, 2 p following 1528
18. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Jama 2000; 284 (10): 1247-1255
19. Henry D, Lim LL-Y, Rodriguez LAG, Gutthann SP, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries JT. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312 (7046): 1563-1566
20. Juni P, Rutjes AW, Dieppe PA. Are selective COX-2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324 (7349): 1287-1288
21. Blanke CD. Celecoxib with chemotherapy in colorectal cancer. Oncology (Huntingt) 2002; 16 (4 Suppl 3): 17-21
22. Edwards JG, Faux SP, Plummer SM, Abrams KR, Walker RA, Waller DA, O'Byrne KJ. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 2002; 8 (6): 1857-1862
23. Ventafridda V, de Conno F, Panerai AE, Maresca V, Monza GC, Ripamonti C. Non-steroidal antiinflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs. J Int Med Res 1990; 18 (1): 21-29
24. Bjorkman R, Hallman KM, Hedner J, Hedner T, Henning M. Acetaminophen blocks spinal hyperalgesia induced by NMDA and substance P. Pain 1994; 57 (3): 259-264
25. Kornhuber J, Maler M, Wiltfang J, Bleich S, Degner D, Ruther E. [Neuronal potassium channel opening with flupirtine]. Fortschr Neurol Psychiatr 1999; 67 (10): 466-475
26. Schwarz M, Schmitt T, Pergande G, Block F. N-methyl-D-aspartate and alpha 2-adrenergic mechanisms are involved in the depressant action of flupirtine on spinal reflexes in rats. Eur J Pharmacol 1995; 276 (3): 247-255
27. Friedel HA, Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 1993; 45 (4): 548-569
28. arznei-telegramm. Leberschäden durch Analgetikum. Flupirtin. 2000; 31 (3): 30
29. Eichelbaum M, Evert B. Influence of pharmacogenetics on drug disposition and response. Clin Exp Pharmacol Physiol 1996; 23 (10-11): 983-985
30. Lewis KS, Han NH. Tramadol: a new centrally acting analgesic. Am J Health Syst Pharm 1997; 54 (6): 643-652
31. Wehrmann T, Rausch D, Seiler KU, Brennscheidt U, Caspary WF. Tilidine does not affect human sphincter of Oddi motility - a randomized, controlled study. Aliment Pharmacol Ther 1997; 11 (5): 987-992
32. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas JR, Sawe J, Twycross RG, Ventafridda V. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84 (5): 587-593
33. Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 1997; 73 (1): 37-45
34. Hagen NA, Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 1997; 79 (7): 1428-1437
35. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 2000; 38 (1): 59-89
36. Donner B, Zenz M, Strumpf M, Raber M. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 1998; 15 (3): 168-175
37. Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53 (1): 109-138
38. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997; 13 (5): 254-261
39. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996; 64 (3): 527-534
40. Arzneimittelkommision-der-deutschen-Ärzteschaft. Therapieempfehlungen Tumorschmerz. 2000; 2
41. Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA, Frigerio V, Ingham J, Loseth DB, Nordbrock E, Rhiner M. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999; 79 (2-3): 303-312
42. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy RK. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001; 911-2.: 123-130
43. Plummer JL, Gourlay GK, Cherry DA, Cousins MJ. Estimation of methadone clearance: application in the management of cancer pain. Pain 1988; 33 (3): 313-322
44. Gorman AL, Elliott KJ, Inturrisi CE. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 1997; 223 (1): 5-8
45. Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, Gebbia V, Ripamonti C. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001; 19 (11): 2898-2904
46. Bulka A, Plesan A, Xu XJ, Wiesenfeld-Hallin Z. Reduced tolerance to the anti-hyperalgesic effect of methadone in comparison to morphine in a rat model of mononeuropathy. Pain 2002; 95 (1-2): 103-109
47. Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, de Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998; 16 (10): 3216-3221
48. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991; 41 (7): 1024-1028
49. Dellemijn PL, Vanneste JA. Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 1997; 349 (9054): 753-758
50. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996; 68 (2-3): 217-227
51. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 1997; 73 (2): 123-139
52. Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1996; 64 (2): 293-302
53. Baron R. [Neuropathic pain. The long path from mechanisms to mechanism-based treatment]. Anaesthesist 2000; 49 (5): 373-386
54. Ventafridda V, Bianchi M, Ripamonti C, Sacerdote P, de Conno F, Zecca E, Panerai AE. Studies on the effects of antidepressant drugs on the antinociceptive action of morphine and on plasma morphine in rat and man. Pain 1990; 43 (2): 155-162
55. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326 (19): 1250-1256
56. Feuerstein TJ. Antidepressiva zur Therapie chronischer Schmerzen. Metaanalyse. Der Schmerz 1997; 11: 213-226
57. McQuay HJ, Moore RA. Antidepressants and chronic pain. Bmj 1997; 314 (7083): 763-764
58. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. Bmj 1995; 311 (7012): 1047-1052
59. McNamara JO. Drugs effective in the Therapy of Epilepsies, in Goodman & Gillman's J.G. Hardman and L.E. Limbird, Editors. The pharmacological Basis of Therapeutics. Mc Graw-Hill: New York, 2001: 521-547
60. Dirks J, Fredensborg BB, Christensen D, Fomsgaard JS, Flyger H, Dahl JB. A randomized study of the effects of single-dose gabapentin versus placebo on postoperative pain and morphine consumption after mastectomy. Anesthesiology 2002; 97 (3): 560-564
61. Caraceni A, Zecca E, Martini C, de Conno F. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 1999; 17 (6): 441-445
62. Clezardin P, Gligorov J, Delmas P. Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis. Joint Bone Spine 2000; 67 (1): 22-29
63. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998; 78 (3): 157-169
64. Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2002; 1: CD003474
65. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 1999; 96 (10): 5780-5785
66. Zygmunt PM, Andersson DA, Hogestatt ED. Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J Neurosci 2002; 22 (11): 4720-4727
67. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Bmj 2001; 323 (7303): 13-16
68. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182 (5A Suppl): 11S-18S
69. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, Swannell AJ, Hawkey CJ. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338 (11): 719-726
70. Eisenberg E, Berkey CS, Carr DB, Mosteller F, Chalmers TC. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994; 12 (12): 2756-2765
71. Mercadante S, Villari P, Ferrera P, Casuccio A, Fulfaro F. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer 2002; 95 (1): 203-208
72. Eisenberg E, Carr DB, Chalmers TC. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg 1995; 80 (2): 290-295
73. Polati E, Finco G, Gottin L, Bassi C, Pederzoli P, Ischia S. Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer. Br J Surg 1998; 85 (2): 199-201
74. Kawamata M, Ishitani K, Ishikawa K, Sasaki H, Ota K, Omote K, Namiki A. Comparison between celiac plexus block and morphine treatment on quality of life in patients with pancreatic cancer pain. Pain 1996; 64 (3): 597-602
75. Gutstein HB, Akil H. Opioid Analgesics J.G. Hardman and L.E. Limbird, Editors. Goodman & Gillman's The pharmacological Basis of Therapeutics Mc Graw-Hill: New York, 2001: 569-620